Benefits of Vitality Complex

By using only premium, organically grown and processed full spectrum hemp for consistency, Vitality Complex brings about the most powerful and efficacious results. [1]

Research Backed Benefits

Reduces Pain and Inflammation

This is the most common reason people are using Vitality Complex. And for good reason, as numerous research over the past several decades have confirmed that cannabinoids are effective and safe for relieving pain. [2] [3] [4]

It has also been proven that cannabinods have an anti-inflammatory effect based on numerous studies. [5]

Helps Maintain Brain Health

Cannabinoids are neuroprotective, meaning that they help maintain and regulate brain health. These effects are a result of numerous actions including:

  • Removal of damaged cells and the improved efficiency of mitochondria [6]
  • Reduces glutamate toxicity [7]
  • Shown to have an anti-inflammatory effect on the brain [8]
  • Encourages the creation of new nerve cells, even in aging brains [9]

Reduces Anxiety and Stress

A number of studies have shown that CBD can lessen anxiety. The stress-reducing effect appears to be related to activity in both the limbic and paralimbic brain areas. [10] 

Improves Sleep

CBD tends to work well, by providing the relaxation and calm for the mental as well as the physical body. When taken at nighttime as part of a bedtime regime it can help produce a restful sleep. [11]

Other Researched Backed Health Benefits of CBD (Cannabidiol)

  • Reduced Risk of Cancer [12] [13] [14]
  • Better Cholesterol Profiles and Lowered Risk of Cardiovascular Disease [15] [16] [17]
  • Reduced Risk of Diabetes and Obesity [18] [19] [20] [21] [22]
  • Protects against Bone Disease and Broken Bones [23]


References:

[1] Ruth Galilly, Z. Yekthin, and L Hanus, "Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol," Pharmacology & Pharmacy 6 (February 2015): 75-85. https://file.scirp.org/Html/5-2500582_53912.htm 

[2] R. Greco, V. Gasperi, M. Maccarrone, and C. Tassorelli, "The Endocannabionid System and Migraine," Experimental Neurology 224, no. 1 (2010): 85-91. https://www.sciencedirect.com/science/article/pii/S0014488610001159?via%3Dihub

[3] S. Maione, F. Piscitelli, L. Gatta, D. Vita, L. De Petrocellis, E. Palazzo, V. de Novellis, and V. Di Marzo, "Non-psychoactive Cannabinoids Modulate the Descending Pathway of Antinociception in Anaesthetized Rats through Several Mechanisms of Action," British Journal of Pharmacology 162, no. 3 (2011): 584. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1476-5381.2010.01063.x

[4] W. Xiong, T. Cui, K. Cheng, F. Yang, S. R. Chen, D. Willenbring, Y. Guan, H.L. Pan, K. Ren, Y. Xu, and L. Zhang, "Cannabinoids Suppress Inflammatory and Neuropathic Pain by Targeting α3 Glycine Receptors," Journal of Experimental Mdicine 209, no. 6 (2012): 1121-1134. http://jem.rupress.org/content/209/6/1121

[5] P. Nagarkatti, R. Pandey, S.A. Rieder, V.L. Hegde, and M. Nagarkatti, "Cannabinoids as Novel Anti-inflammatory Drugs," Future Medicinal Chemistry 1, no. 7 (2009): 1333-1349, http://doi.org/10.1016/j.cpr.2011.01.006

[6] Andras Bilkei-Gorzo, “The Endocannabinoid System in Normal and Pathological Brain Ageing,” Philosophical Transactions of the Royal Society of London 367, no. 1607 (2012): 3326–3341. https://royalsocietypublishing.org/doi/full/10.1098/rstb.2011.0388

[7] Ashok K. Shetty, "Promise of resveratrol for easing status epilepticus and epilepsy," Pharmacol Ther. 2011 Sep; 131(3): 269–286. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133838/#

[8] J. Fernández-Ruiz, O. Sagredo, M. R. Pazos, C. García, R. Pertwee, R. Mechoulam, and J. Martínez-Orgado, “Cannabidiol for Neurodegenerative Disorders: Important New Clinical Applications for This Phytocannabinoid?” British Journal of Clinical Pharmacology 75, no. 2 (May 25, 2012): 323–333. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2125.2012.04341.x

[9] Gary L. Wenk, “Animal Models of Alzheimer’s Disease,” Animal Models of Neurological Disease I (1992): 29–64, https://link.springer.com/protocol/10.1385%2F0-89603-208-6%3A29.

[10] A. R. Schier, N. P. Ribeiro, A. C. Silva, J. E. Hallak, J. A. Crippa, A. E. Nardi, and A. W. Zuardi, “Cannabidiol, a Cannabis sativa Constituent, As an Anxiolytic Drug,” Revista Brasileira de Psiquiatri 34, suppl. 1 (2012): S104–S110. PubMed PMID: 22729452. https://www.ncbi.nlm.nih.gov/pubmed/22729452

[11] Leonard Leinow and Juliana Birnbaum, "CBD - A Patient's Guide To Medical Cannabis," North Atlantic Books, Berkley, California (2017): 166-167.

[12] Gabriella Aviello, Barbara Romano, Francesca Borrelli, Raffaele Capasso, Laura Gallo, Fabiana Piscitelli, Vincenzo Di Marzo, and Angelo A. Izzo, “Chemopreventive Effect of the Non-psychotropic Phytocannabinoid Cannabidiol on Experimental Colon Cancer,” Journal of Molecular Medicine 90, no. 8 (2012): 925–934. https://link.springer.com/article/10.1007%2Fs00109-011-0856-x

[13] “NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)- Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1Mice (Gavage Studies),” National Toxicology Program Technical Report Series 446 (1996): 1–317 https://www.ncbi.nlm.nih.gov/pubmed/12594529

[14] A. A. Thomas, L. P. Wallner, V. P. Quinn, J. Slezak, S. K. Van Den Eeden, G. W. Chien, and S. J. Jacobsen, “Association between Cannabis Use and the Risk of Bladder Cancer: Results from the California Men’s Health Study,” Urology 85, iss. 2 (2015): 388–393. https://www.ncbi.nlm.nih.gov/pubmed/25623697

[15] Sabine Steffens, Niels R. Veillard, Claire Arnaud, Graziano Pelli, Fabienne Burger, Christian Staub, Andreas Zimmer, Jean-Louis Frossard, and François Mach, “Low Dose Oral Cannabinoid Therapy Reduces Progression of Atherosclerosis in Mice,” Nature 434 (2005): 782–786. https://www.ncbi.nlm.nih.gov/pubmed/15815632

[16] Francois Mach and Sabine Steffens, “The Role of the Endocannabinoid System in Atherosclerosis,” Journal of Neuroendocrinology 20, no. S1 (2008): 53–57. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2826.2008.01685.x

[17] Mauro Maccarrone, Itai Bab, Tamás Bíró, Guy A. Cabral, Sudhansu K. Dey, Vincenzo Di Marzo, Justin C. Konje, George Kunos, Raphael Mechoulam, Pal Pacher, Keith A. Sharkey, and Andreas Zimmer, “Endocannabinoid Signaling at the Periphery, 50 Years after THC,” Cell: Trends in Pharmacological Science 36, no. 5 (May 2015): 277–296. https://www.ncbi.nlm.nih.gov/pubmed/25796370

[18] Yann LeStrat and Bernard Le Foll, “Obesity and Cannabis Use: Results From 2 Representative National Surveys,” American Journal of Epidemiology 174, no. 8 (2011): 929–933. https://www.ncbi.nlm.nih.gov/pubmed/21868374

[19] L. Weiss, M. Zeira, S. Reich, M. Har-Noy, R. Mechoulam, S. Slavin, and R. Gallily, “Cannabidiol Lowers Incidence of Diabetes in Non-obese Diabetic Mice,” Autoimmunity 39, no. 2 (2006): 143–151. https://www.ncbi.nlm.nih.gov/pubmed/16698671

[20] Abigail Klein Leichman, “Cannabis Extract to Be Used to Treat Diabetes,” Israel 21c, April 21, 2015, www.israel21c.org/cannabis-extract -to-be-used-to-treat-diabetes/.

[21] H. J. Parray and J. W. Yun, “Cannabidiol Promotes Browning in 3T3-L1 Adipocytes,” Molecular and Cellular Biochemistry 416 (2016): 131–139. https://www.ncbi.nlm.nih.gov/pubmed/27067870

[22] E. A. Penner, H. Buettner, and M. A. Mittleman, “Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults,” American Journal of Medicine 126 (2013): 583–589. https://www.ncbi.nlm.nih.gov/pubmed/23684393

[23] N. M. Kogan, E. Melamed, E. Wasserman, B. Raphael, A. Breuer, K. S. Stok, R. Sondergaard, A. V. Escudero, S. Baraghithy, M. Attar-Namdar, S. Friedlander-Barenboim, N. Mathavan, H. Isaksson, R. Mechoulam, R. Müller, A. Bajayo, Y. Gabet, and I. Bab, “Cannabidiol, A Major Nonpsychotropic Cannabis Constituent, Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts,” Journal of Mineral and Bone Research 30, no. 10 (October 2015): 1905–1913. https://www.ncbi.nlm.nih.gov/pubmed/25801536